Metrics as of 10/17/2026, 08:46 AM (Berlin time), refresh in progress.
PDS Biotechnology Stock
PDS Biotechnology Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Frank K. Bedu-Addo
- Employees
- 21
- Market cap
- $63 M
- IPO
- 30/09/2015
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or…
PDS Biotechnology stock: price history
1D
-13.1%
1W
-18.1%
1M
+14.1%
6M
-13.7%
YTD
+46.8%
1Y
+19.5%
2Y
-64.4%
5Y
-90.8%
10Y
-99.5%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~40% stronger price swings than usual
Ask the agents about PDS Biotechnology
Analyst assessment of PDS Biotechnology
PRICE TARGET LOW
US$9.00
CONSENSUS
US$9.00
MEDIAN
US$9.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
6
BUY
1
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 08/09/2026
PDS Biotechnology stock metrics
P/E
-1.77
P/B
-17.57
EV/EBITDA
-2.29
RETURN ON EQUITY
272.4%
NET MARGIN
0.0%
DEBT/EQUITY
-1.22
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.3%
FLOAT SHARES
55,003,892
AVG. DAILY VOLUME (30D)
49,848,108
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about PDS Biotechnology stock
What does PDS Biotechnology do?
PDS Biotechnology Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Frank K. Bedu-Addo, the company employs around 21 people.
The IPO was on 30/09/2015; the stock trades on NASDAQ under the ticker PDSB.
What do analysts say about PDS Biotechnology stock?
7 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$9.00, ranging from US$9.00 to US$9.00, with a median of US$9.00.
This is an external assessment, not a statement by Market Jury.
When does PDS Biotechnology report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 40% stronger than usual.
Does PDS Biotechnology pay a dividend?
No, PDS Biotechnology currently does not pay a dividend.
Which stocks are comparable to PDS Biotechnology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get PDS Biotechnology stock analyzed?
Clicking "Analyze stock" lets five strategies assess PDS Biotechnology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.